-
September 26, 2023Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia
Elpiscience Biopharmaceuticals announced that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.
-
March 17, 2023Elpiscience to Present at BIO-Europe Spring 2023 in Basel
Join us at BIO-Europe Spring 2023.
-
February 27, 2023Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-β Bispecific Antibody ES014
Elpiscience Biopharmaceutical today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb).
-
January 04, 2023Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during J.P. Morgan Week 2023
Elpiscience today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase™ conference during J.P.Morgan
-
December 23, 2022Elpiscience Announces China CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
Elpiscience today announced that the China Center of Drug Evaluation (CDE) has cleared Elpiscience’s Investigational New Drug Application (IND) for ES014 to initiate a Phase 1 clinical study for
-
November 18, 2022Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting
Elpiscience presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting